Helping people with dementia retain their independence

The Longitude Prize on Dementia is a £4.42 million prize

The Longitude Prize on Dementia will drive the creation of personalised, technology-based tools that are co-created with people living with the early stages of dementia, helping them live independent, more fulfilled lives so they are able to do the things they enjoy.

After a global search and entries from around the world, our five Finalists have now been selected! We are so excited to announce the teams that will continue developing and validating their solutions, for the chance to win the £1 million grand prize. Each Finalist team has been awarded a £300,000 grant to help further develop their solution over the next 15 months in readiness for final submission, ahead of the winner announcement in early 2026.

The final £1 million prize will be awarded to the creator of a breakthrough technology that will enable people living with dementia to continue living independently for longer.

Meet the Finalists

Prize timeline

Prize Launch

Entries to the Discovery Awards opened on 26 September 2022 and closed on 26 January 2023 at 2359 GMT. Entries will be evaluated and 24 Discovery Awardees will be selected to move forward in the Prize.

Pavement and two pairs of shoes facing text on the pavement that says

Discovery Award Application Window

Grants of £80,000 will be provided to the Discovery Awardees to support the development and validation of their solutions. Five finalists will be chosen to move on.

Yellow person with blue hair on the screen of a phone holding a little world. It says

Finalists stage

Grants of £300,000 will be provided to the Finalists to support the development and validation of their solutions. Finalists will participate in 15 months of further capacity building support to help consolidate plans for developing solutions.

Winner Announcement

One winner will be selected to receive a grant of £1,000,000 (£1m). The winning solution selected will be a digital device or service designed for use by people living with dementia as the primary users.